Collagen Matrix has received an undisclosed investment from Metalmark Capital. RBC Capital Markets was financial advisor on the transaction. Headquartered in Oakland, NJ, Collagen Matrix is a provider of products and technology used in tissue repair and regeneration.
October 27, 2014 08:00 AM Eastern Daylight Time
OAKLAND, N.J.–(BUSINESS WIRE)–Collagen Matrix, Inc., (“Collagen Matrix”) a leading provider of high quality products and technology used in tissue repair and regeneration, today announced the completion of a majority investment by Metalmark Capital, a New York-based private equity firm. Metalmark’s investment in Collagen Matrix will provide the resources, expertise and capital needed to continue to grow the business. As part of the transaction, Collagen Matrix’s management team, including founder, Dr. Shu-Tung Li, will remain with the company. Financial terms were not disclosed.
“We are excited about this opportunity to partner with Metalmark Capital,” said Dr. Shu-Tung Li, Founder, President and CEO of Collagen Matrix, Inc. “Over the past 17 years, Collagen Matrix has grown into a leading medical technology company with innovation at the heart of our work. Metalmark’s partnership brings a strong knowledge of the sector as well as access to additional capital and resources that will advance the next chapter of our growth and expand our leadership role in tissue repair and regeneration.”
“Under the leadership of Dr. Shu-Tung Li, Collagen Matrix has become an industry leader that designs, develops, manufactures and markets high quality collagen- and mineral-based products, all of which are delivered through exemplary customer service,” said Fazle Husain, Managing Director at Metalmark Capital. “We look forward to partnering with the Collagen Matrix management team to support the company in raising its existing business and proprietary technology to a higher level of world-class leadership. This investment broadens Metalmark’s presence in medical devices and strengthens our portfolio in healthcare, an important growth area for the firm.”
Founded in 1997, Collagen Matrix has expanded beyond the sales of its first product, a collagen membrane used in oral surgery, to include the sales of over 30 medical devices in more than forty countries worldwide. The company’s proprietary technology is protected by numerous patents that speak to successful expansion of sales growth across the healthcare sectors of Oral/Maxillofacial surgery,
Neurosurgery and Orthopaedic/Spine surgery. Recent worldwide launches of new products such as OssiMendTM Bone Graft Matrix, DuraMatrix-OnlayTM Conformable Collagen Dura Substitute Membrane, and a new family of products for oral surgery have increased Collagen Matrix’s product portfolio and led to an expansion to a world-class 28,000 sq. ft. manufacturing facility that will continue to serve as the company’s corporate headquarters. Additionally, Collagen Matrix has successfully achieved many marketing, private label and distribution agreements with medical device industry leaders, to benefit consumers on a global scale.
Financial and Legal Advisors
RBC Capital Markets, LLC acted as financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor to Collagen Matrix, Inc. on the transaction.
Ropes & Gray LLP acted as legal advisor to Metalmark Capital.
About Metalmark Capital
Metalmark Capital is a leading private equity firm whose principals have a long track record of successful investing in targeted sectors, with particular expertise and focus in healthcare, energy and industrials. Metalmark Capital seeks to build long-term value through active and supportive partnerships with the companies and management teams in which it invests. Metalmark Capital is currently investing its latest fund with $2.5 billion of committed capital. For more information, please visit www.metalmarkcapital.com.
About Collagen Matrix
Collagen Matrix, Inc. is a leader in the design and engineering of collagen- and mineral-based extracellular matrices for tissue and organ repair and regeneration. Since its inception in 1997, the Company has received many government grants for the development of innovative, collagen-based matrix products in the areas of neurological, vascular, urological, and orthopedic tissue regeneration applications. The Company currently manufactures collagen-based finished medical devices in the areas of oral/maxillofacial surgery, neurosurgery, and orthopedic-spine surgery. For more information about the Company, please visit www.collagenmatrix.com.